endogenous retrovirus group H member 1Genealiases: []
Q-omics provides the consensus-scored ERVH-1 profile across patient tissues and cancer cell-line models. ERVH-1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ERVH-1 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, ERVH-1 RNA expression shows 6,879 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, HNSC, and STAD as cancer lineages where ERVH-1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ERVH-1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ERVH-1 survival associations across molecular data types. ERVH-1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ERVH-1 RNA expression–survival associations across cancer types. High ERVH-1 expression shows unfavorable associations in LUSC, BRCA and UCEC, but favorable associations in KIRP, BLCA and MESO. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify KIRP as the clearest survival context for ERVH-1 RNA expression.
This table summarizes ERVH-1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ERVH-1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ERVH-1 shows lower tumor expression in COAD and READ and higher tumor expression in HNSC, KIRP, LIHC and LUSC. The HNSC box plot shows higher ERVH-1 RNA expression in tumor versus normal tissue (log2 FC = +0.059, t-test p = .001).
This table shows molecular features associated with ERVH-1 in patient tissues and cancer cell lines. In patient samples, ERVH-1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
